Next Article in Journal
Physical Stimulation Combined with Biomaterials Promotes Peripheral Nerve Injury Repair
Previous Article in Journal
Selected Flavonoids to Target Melanoma: A Perspective in Nanoengineering Delivery Systems
 
 
Review

Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics

State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing 210023, China
*
Author to whom correspondence should be addressed.
Academic Editor: Hanieh Khalili
Bioengineering 2022, 9(7), 291; https://doi.org/10.3390/bioengineering9070291
Received: 31 May 2022 / Revised: 22 June 2022 / Accepted: 27 June 2022 / Published: 29 June 2022
(This article belongs to the Special Issue Bioengineering of Biotherapeutics)
Over the past decades, RNA viruses have been threatened people’s health and led to global health emergencies. Significant progress has been made in diagnostic methods and antiviral therapeutics for combating RNA viruses. ELISA and RT-qPCR are reliable methods to detect RNA viruses, but they suffer from time-consuming procedures and limited sensitivities. Vaccines are effective to prevent virus infection and drugs are useful for antiviral treatment, while both need a relatively long research and development cycle. In recent years, CRISPR-based gene editing and modifying tools have been expanded rapidly. In particular, the CRISPR-Cas13 system stands out from the CRISPR-Cas family due to its accurate RNA-targeting ability, which makes it a promising tool for RNA virus diagnosis and therapy. Here, we review the current applications of the CRISPR-Cas13 system against RNA viruses, from diagnostics to therapeutics, and use some medically important RNA viruses such as SARS-CoV-2, dengue virus, and HIV-1 as examples to demonstrate the great potential of the CRISPR-Cas13 system. View Full-Text
Keywords: CRISPR; Cas13 system; RNA viruses; diagnostics; therapeutics CRISPR; Cas13 system; RNA viruses; diagnostics; therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Xue, Y.; Chen, Z.; Zhang, W.; Zhang, J. Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics. Bioengineering 2022, 9, 291. https://doi.org/10.3390/bioengineering9070291

AMA Style

Xue Y, Chen Z, Zhang W, Zhang J. Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics. Bioengineering. 2022; 9(7):291. https://doi.org/10.3390/bioengineering9070291

Chicago/Turabian Style

Xue, Yi, Zhenzhen Chen, Wenxian Zhang, and Jingjing Zhang. 2022. "Engineering CRISPR/Cas13 System against RNA Viruses: From Diagnostics to Therapeutics" Bioengineering 9, no. 7: 291. https://doi.org/10.3390/bioengineering9070291

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop